New opioid prescriptions for U.S. adults using benzodiazepines stopped increasing in 2010, although the likelihood of receiving a prescription is still elevated versus the general population.
Dr Gould covered the risks of co-prescribing benzodiazepines and opioids, particularly for elderly patients, and proposed therapeutic alternatives at PAINWeek 2017.
Jennifer Bolen, JD, provides PAINWeek 2017 attendees with information on risk reduction and response to medication overdose events.
Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by a tool used to assess fracture risk in the general population.
Clobazam is more effective than placebo in reducing low back pain.
Throughout 2016, the FDA has announced requirements for manufacturers to create new product labeling information for a variety of opioid medications.
Meta-analysis shows muscle relaxants are effective in reducing acute but not chronic low back pain.
Clinical Pain Advisor Articles
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?